文献速递临床试验与 GCP流行病学与生物统计

早期试验的疗效与安全性效应估计在III期试验中发生回归

Early-phase trial efficacy and safety effect estimates regress upon testing in phase 3 trials.
PubMed 文献 · J Clin Epidemiol · 2026-01-19

该研究将2014至2020年完成的III期实体瘤试验与支持性Ib/II期试验按同一药物-适应症配对,评估客观缓解率、中位总生存期和严重不良事件的相关性。87对配对中三者均呈正相关且显著,但III期估计更常低于早期估计而非高于。作者认为早期试验估计用于临床决策时需谨慎。

要点

  • 87对Ib/II期-III期配对中,客观缓解率、中位总生存期和严重不良事件率均呈显著正相关。
  • III期估计低于早期估计的可能性至少是高于的两倍。
  • 作者认为早期试验估计用于临床决策时需谨慎,III期试验对治疗决策仍必不可少。

核心结论

  • 实体瘤药物Ib/II期试验的疗效和毒性估计在III期中常发生回归。
  • 早期与确证性试验间的变异性凸显了用早期估计做临床决策时需谨慎。

研究设计与样本

  • 研究识别2014至2020年完成的III期实体瘤试验,并将每个III期试验与测试同一药物-适应症配对的支持性Ib/II期试验匹配。
  • 共识别87对Ib/II期-III期配对,评估客观缓解率、中位总生存期和严重不良事件的相关性。
  • 研究还评估III期效应量是否落入Ib/II期结果的95%置信区间,以及试验设计特征是否影响回归。

主要发现

  • 87对配对中,客观缓解率呈正相关且显著(β=0.78,校正R²=0.549,P<.001)。
  • 中位总生存期呈正相关且显著(β=0.67,校正R²=0.523,P<.001)。
  • 严重不良事件率呈正相关且显著(β=0.54,校正R²=0.285,P<.001)。
  • III期偏倚风险低时客观缓解率的回归(β=0.660,校正R²=0.445)大于偏倚风险高时(β=1.00,R²=0.704)。
  • III期估计低于Ib/II期估计的可能性至少是高于的两倍(客观缓解率:21% vs 10%;中位总生存期:25% vs 6%;严重不良事件:22% vs 4%)。

临床怎么用

  • 作者认为早期癌症试验有助于发现有前景的治疗,但不能可靠预测这些治疗在常规诊疗中的效果。
  • 作者认为仔细开展的III期试验对癌症治疗决策仍必不可少。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Many drug development and care decisions rest on phase Ib or II trial evidence, which may overestimate efficacy due to regression to the mean or bias. The objective of the study was to assess concordance between efficacy and safety estimates from phase Ib/II (P1b/2) and subsequent phase III (P3) solid tumor therapy trials. STUDY DESIGN AND SETTING: We identified P3 solid tumor trials completed 2014-2020, and then matched each to supporting phase P1b/2 trial(s) testing the same drug-indication pairing. Correlation was assessed for objective response rate (ORR), median overall survival (mOS), and serious adverse events (SAEs). We also assessed whether P3 effect sizes fell within 95% CIs of P1b/2 results and whether trial design features influenced regression. RESULTS: In 87 P1b/2-P3 identified pairings, correlations were positive and significant for ORR (β = 0.78, adj. R2 = 0.549, P < .001), mOS (β = 0.67, adj. R2 = 0.523, P < .001), and SAE rates (β = 0.54, adj. R2 = 0.285, P < .001). Regression was greater when P3 had a low risk of bias (RoB) for ORR (β = 0.660, adj. R2 = 0.445) than when RoB was high (β = 1.00, R2 = 0.704). P3 estimates were at least twice as likely to fall below P1b/2 estimates than above (ORR: 21% vs 10%; mOS: 25% vs 6%; SAE: 22% vs 4%). CONCLUSION: Efficacy and toxicity estimates from P1b/2 trials of solid tumor drugs often regress in P3. The variability between early and confirmatory trials underscores the need for caution when interpreting early-phase estimates for clinical decisions. PLAIN LANGUAGE SUMMARY: Phase Ib and II clinical trials play an important role in the cancer drug development. They are often used to decide whether a treatment should move forward to larger P3 trials and, in some cases, to support regulatory approval or clinical recommendations. However, results from early-phase trials may overestimate a drug's effects. We wanted to know how closely early trial results match what is later seen in P3 trials. We compared early and later trials that tested the same drug for the same type of solid tumor, looking at how often patients' tumors shrink, how long they live, and how often severe adverse events occur. We found that results from early and later trials were related, but early trials usually had better efficacy results. On average, early trials overstated tumor response rates by about one-fifth. However, SAEs were often less common than early trials suggested. This matters because early-phase trial results are widely used to guide drug approvals, clinical guidelines, and health care spending. In cancer care, treatments are sometimes adopted based mainly on early results, and many early trials are never followed by definitive P3 studies. Our findings suggest that early cancer trials are useful for spotting promising treatments, but they are not a reliable guide to how well those treatments will work in routine care. Careful P3 trials remain essential for making decisions about cancer treatment.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Nelson A, Moyer H, Vigneault K, et al. Early-phase trial efficacy and safety effect estimates regress upon testing in phase 3 trials. J Clin Epidemiol. 2026. PMID: 41565164. doi:10.1016/j.jclinepi.2026.112149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。